AOLS.US Aeolus Pharmaceuticl
- Market cap
- USD 15.2K
- P/E
- -
- P/B
- 0.81x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2023.
Is AOLS.US undervalued?
Graham numberThe Graham number of Aeolus Pharmaceuticl cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aeolus Pharmaceuticl fundamental analysis
No fundamental analysis for Aeolus Pharmaceuticl yet.
Aeolus Pharmaceuticl stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aeolus Pharmaceuticl
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound inc…
Full company profileAeolus Pharmaceuticl financial statements
Aeolus Pharmaceuticl annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.29M | 3.93M | 9.63M | 3.11M | 2.08M | - | - | - | - | - |
| Gross Profit | 7.29M | 568K | 9.63M | 3.11M | 2.08M | - | - | - | - | - |
| Operating Income | -2.37M | -2.70M | -80.0K | -2.63M | -3.27M | - | - | - | - | - |
| EBITDA | -2.36M | -2.69M | -80.0K | -2.63M | -3.27M | - | - | - | - | - |
| Net Income | 1.70M | -3.21M | -80.0K | -2.63M | -3.56M | - | - | - | - | - |
| EPS | 0.02 | -0.03 | 0.00 | -0.02 | -0.02 | - | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 1.26M | 1.97M | 3.58M | 1.78M | 4.17M | - | - | - | - | - |
| Total Liabilities | 21.6M | 1.26M | 2.00M | 2.62M | 972K | - | - | - | - | - |
| Shareholders' Equity | -20.3M | 705K | 1.59M | -845K | 3.20M | - | - | - | - | - |
| Cash & Short-term Investments | 281K | 869K | 1.52M | 94.0K | 3.16M | - | - | - | - | - |
| Total Debt | - | - | - | 1.00M | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -879K | -2.97M | 323K | -2.44M | -3.11M | - | - | - | - | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - |
| Free Cash Flow | -879K | -2.97M | 323K | -2.44M | -3.11M | - | - | - | - | - |
| Ratios | ||||||||||
| ROE | - | -455.0% | -5.0% | - | -111.4% | - | - | - | - | - |
| ROA | 135.2% | -163.2% | -2.2% | -147.9% | -85.4% | - | - | - | - | - |
| Net Profit Margin | 23.3% | -81.7% | -0.8% | -84.5% | -171.4% | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aeolus Pharmaceuticl dividends
Aeolus Pharmaceuticl has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jul 16, 2004.
Who owns Aeolus Pharmaceuticl
Ownership data of Aeolus Pharmaceuticl is not available yet.
Aeolus Pharmaceuticl company profile
- Company name
- Aeolus Pharmaceuticl
- Ticker
- AOLS.US
- Exchange
- USA Stocks
- Listed since
- Feb 1, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4
- Fiscal year end
- September
- Address
- 27800 Medical Center Rd, Mission Viejo, CA, United States, 92691
- Phone
- 949 485 9621
- Website
- aeoluspharma.com
About Aeolus Pharmaceuticl
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11207 for the treatment of Parkinson's disease. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.
Aeolus Pharmaceuticl management
1- Mr. Christopher StanleyVice President of Operations